Percentage of Positive Biopsy Cores: A Better Risk Stratification Model for Prostate Cancer?

Huang, Jiayi; Vicini, Frank A.; Williams, Scott; Ye, Hong; McGrath, Samuel; Ghilezan, M.; Krauss, Daniel; Martínez, Álvaro; Kestin, Larry L.

doi:10.1016/j.ijrobp.2011.09.043

Cited by 57 publications

(42 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Low risk and favorable intermediate risk patients may be treated with HDR brachytherapy monotherapy (5,6,12,14). Unfavorable intermediate risk patients had a Gleason score of 4+3=7, cT2c disease, or >50% positive core biopsies (15,16). Patients with unfavorable intermediate risk prostate cancer and patients who received intensity modulated radiation therapy (IMRT) or androgen deprivation therapy were excluded from this study.…”

Section: Methodsmentioning

confidence: 99%

Quality of life after high-dose rate brachytherapy monotherapy for prostate cancer.

Contreras

Wilder

Mellon

et al. 2014

JCO

View full text Add to dashboard Cite

show abstract

Section: Methodsmentioning

confidence: 99%

Quality of life after high-dose rate brachytherapy monotherapy for prostate cancer.

Contreras

Wilder

Mellon

et al. 2014

JCO

View full text Add to dashboard Cite

show abstract

“…In a cohort of low-and favorable intermediate-risk men treated with definitive radiotherapy, >50% biopsy cores positive was significantly associated with worse PCSM (13). In another study of more than 1,000 patients with cT1c-T3N0M0 prostate cancer treated with external beam radiotherapy with or without a high-dose-rate brachytherapy boost, the percentage of cores positive was associated with rates of distant metastasis, cause-specific survival, and overall survival (14). Further reinforcing the prognostic importance of the volume of disease in prostate cancer treated with radiotherapy, the percentage of cancer volume in biopsy cores has been shown to be prognostic for biochemical failure, distant metastasis, cause-specific survival, and overall survival, even in patients treated with dose-escalated external beam radiotherapy (15).…”

Section: Resultsmentioning

confidence: 93%

Imaging and Pathology Correlations for Different Risk Stratification Models for Intermediate-risk Prostate Cancer

Ellis-Caleo

Hegde

Batth

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Association of PPC with distant metastases (DM) and correlation of PPC with OS were reported in high risk patients. 28 More quantitative assessments of biopsy tumor volume, such as percentage of tumor volume (PCV) have been studied in the context of RP, brachytherapy, androgen deprivation therapy, External RT or combined treatments. These studies all suggested that the PCV is a more discriminating prognostic variable than the PPC.…”

Section: Discussionmentioning

confidence: 99%

Three Dimensional Conformal Radiotherapy and Androgen Deprivation Therapy in Patients with Clinically Localized Prostate Cancer; Hacettepe University Experience

Özdemir¹,

Akyol²,

Özyiğit³

et al. 2015

UHOD

View full text Add to dashboard Cite

The aim of this study is to evaluate the treatment results of three dimensional conformal radiotherapy (3DCRT) and androgen deprivation therapy (ADT) in patients with clinically localized prostate cancer (CLPC). Between June 1998 and December 2011, 577 patients with the diagnosis of CLPC were treated. ADT was started 3 months prior to radiotherapy (RT). 3DCRT was delivered to prostate and the seminal vesicles (SV) to a total dose of 70Gy. Additionally, patients with lymph node (LN) positivity received 50.4Gy RT to pelvic LN's. Median follow up time was 65 months. Five-ten years overall survival (OS), cause specific survival (CSS), PSA relapse-free survival (PSA-RFS) and distant metastasis-free survival (DMFS) rates were 92-74%, 97-91%, 77-55% and 94-88%, respectively. OS was negatively affected from LN positivity (p< 0.001). In the subgroup of patients with GS≥ 8, there was no significant difference between < 1 years and ≥ 1 years of ADT in terms of CSS, PSA-RFS and DMFS. OS was better in patients with < 1 years of ADT (p= 0.01). Five year OS (p= 0.02), CSS (p= 0.05), PSA-RFS (p= 0.01) and DMFS (p= 0.07) rates were inferior in the high risk group patients that used ADT ≥ 1 year. Acute and late RTOG grade III/IV gastrointestinal system toxicity rates were 1.7% and 5% and acute and chronic RTOG grade III/IV genitourinary system toxicity rates were 1.4% and 5%, respectively. 3DCRT and ADT combination is an effective treatment modality with acceptable toxicities in patients with clinically localized prostate cancer. Keywords: Prostate cancer, Conformal radiotherapy, Androgen deprivation therapy ÖZET Lokalize Prostat Kanserli Olgularda Üç Boyutlu Konformal Radyoterapi ve Total Androjen Blokajı; Hacettepe Üniversi-tesi DeneyimiBu çalışmanın amacı, üç boyutlu konformal radyoterapi (3BKRT) ve total androjen blokajı (TAB) Lokalize prostat kanserli olgularımızdaki tedavi sonuçlarımızı değerlendirmek. Haziran 1998 ve Aralık 2011 tarihleri arasında lokalize prostat kanseri tanısıyla 577 olgu tedavi edildi. TAB tedavisine radyoterapiden (RT) 3 ay sonar başlandı. 3BKRT olarak prostat ve seminal veziküllere toplam 70 Gy uygulandı. Ek olarak lenf nodu (LN) tutulumu olan olgularda pelvic LN'larına 50.4 Gy uygulandı. Ortanca izlem süresi 65 aydır. Beş-on yıllık genel sağkalım (GS), hastalığa özgü sağkalım (HSS), PSA-relapssız sağkalım (PSA-RFS) ve uzak metastazsız sağkalım (DMFS) oranları sırasıyla %92-74, %97-91, %77-55 ve %94-88 bulundu. LN tutulumu GS'ı olumsuz etkilemiştir (p< 0.001). Gleason skoru ≥ 8 olan olgularda <1 yıl ile ≥ 1yıl TAB kullanımı arasında HSS, PSA-RFS ve DMFS açısından fark yoktu. Ancak <1 yıl TAB kullananlarda GS daha iyiydi (p= 0.01). Yüksek riskli grupta olup ≥ 1yıl TAB kullanan hastalarda 5 yıllık GS (p= 0.02), HSS (p= 0.05), PSA-RFS (p= 0.01) ve DMFS (p= 0.07) daha düşük bulundu. Erken ve geç dönem RTOG grad III/IV gastrointestinal sistem toksisite oranları %1.7 ve %5 bulundu. Erken ve geç dönem RTOG grad III/IV genitoüriner sistem toksisite oranları %1.4 ve %5 bulundu. Lokalize prostat kanseri...

show abstract

Percentage of Positive Biopsy Cores: A Better Risk Stratification Model for Prostate Cancer?

Cited by 57 publications

References 20 publications

Quality of life after high-dose rate brachytherapy monotherapy for prostate cancer.

Quality of life after high-dose rate brachytherapy monotherapy for prostate cancer.

Imaging and Pathology Correlations for Different Risk Stratification Models for Intermediate-risk Prostate Cancer

Three Dimensional Conformal Radiotherapy and Androgen Deprivation Therapy in Patients with Clinically Localized Prostate Cancer; Hacettepe University Experience

Contact Info

Product

Resources

About